CN102007140B - 生物活性肽 - Google Patents

生物活性肽 Download PDF

Info

Publication number
CN102007140B
CN102007140B CN200980114502.4A CN200980114502A CN102007140B CN 102007140 B CN102007140 B CN 102007140B CN 200980114502 A CN200980114502 A CN 200980114502A CN 102007140 B CN102007140 B CN 102007140B
Authority
CN
China
Prior art keywords
peptide
seq
seqidno
fviii
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980114502.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102007140A (zh
Inventor
弗里德里希·沙伊夫林格
米夏埃尔·道卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to CN201610040575.5A priority Critical patent/CN105524163A/zh
Publication of CN102007140A publication Critical patent/CN102007140A/zh
Application granted granted Critical
Publication of CN102007140B publication Critical patent/CN102007140B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN200980114502.4A 2008-04-17 2009-04-16 生物活性肽 Expired - Fee Related CN102007140B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610040575.5A CN105524163A (zh) 2008-04-17 2009-04-16 生物活性肽

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US932608P 2008-04-17 2008-04-17
US61/009,326 2008-04-17
US11305508P 2008-11-10 2008-11-10
US61/113,055 2008-11-10
PCT/US2009/040857 WO2009137256A1 (en) 2008-04-17 2009-04-16 Biologically active peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610040575.5A Division CN105524163A (zh) 2008-04-17 2009-04-16 生物活性肽

Publications (2)

Publication Number Publication Date
CN102007140A CN102007140A (zh) 2011-04-06
CN102007140B true CN102007140B (zh) 2016-02-24

Family

ID=40887122

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980114502.4A Expired - Fee Related CN102007140B (zh) 2008-04-17 2009-04-16 生物活性肽
CN201610040575.5A Pending CN105524163A (zh) 2008-04-17 2009-04-16 生物活性肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610040575.5A Pending CN105524163A (zh) 2008-04-17 2009-04-16 生物活性肽

Country Status (19)

Country Link
US (6) US8563688B2 (enExample)
EP (2) EP2279200B1 (enExample)
JP (3) JP6038452B2 (enExample)
KR (2) KR101606248B1 (enExample)
CN (2) CN102007140B (enExample)
AR (1) AR071478A1 (enExample)
AU (1) AU2009244635B2 (enExample)
BR (1) BRPI0911203A2 (enExample)
CA (1) CA2721694C (enExample)
DK (2) DK2279200T3 (enExample)
ES (2) ES2739676T3 (enExample)
HK (1) HK1223946A1 (enExample)
MX (1) MX2010011397A (enExample)
NZ (1) NZ588200A (enExample)
PL (1) PL2279200T3 (enExample)
PT (1) PT2279200T (enExample)
SG (2) SG10201809286XA (enExample)
TW (2) TWI573806B (enExample)
WO (1) WO2009137256A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2012012444A2 (en) 2010-07-19 2012-01-26 Dolby Laboratories Licensing Corporation Enhancement methods for sampled and multiplexed image and video data
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
BR112015028502B1 (pt) * 2013-06-11 2022-03-22 Cj Cheiljedang Corporation Microrganismo produtor de l-isoleucina e método para a produção de l-isoleucina utilizando o mesmo
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
US9321812B2 (en) 2014-03-28 2016-04-26 Perle Bioscience Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide
JP6484468B2 (ja) * 2014-06-03 2019-03-13 ＡｖａｎＳｔｒａｔｅ株式会社 ガラス板製造方法およびガラス板製造装置
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
EP3519431A1 (en) 2016-09-28 2019-08-07 Cohbar Inc. Therapeutic mots-c related peptides
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
BR112019015569A2 (pt) 2017-01-31 2020-03-17 Bioverativ Therapeutics Inc. Proteínas de fusão do fator ix e métodos para a sua produção e uso
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124544A1 (en) * 2001-10-17 2005-06-09 Claude Granier Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CA2155947C (en) * 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
WO1996021024A1 (en) * 1994-12-30 1996-07-11 Asgrow Seed Company Papaya ringspot virus replicase gene
US5532153A (en) * 1995-03-23 1996-07-02 New England Biolabs, Inc. Method for cloning and producing the SacI restriction endonuclease
US7279548B2 (en) * 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
US6197526B1 (en) * 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
AU781618C (en) * 1999-07-02 2006-03-16 Genentech Inc. FVIIa antagonists
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US20020018778A1 (en) * 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
WO2001058479A1 (en) * 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
EP1385872A4 (en) * 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
US20060204503A1 (en) * 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
CA2635975A1 (en) 2006-01-04 2007-07-12 Do-Coop Technologies Ltd. Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
AR071478A1 (es) * 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124544A1 (en) * 2001-10-17 2005-06-09 Claude Granier Peptide decoys for the preparation of medicaments intended for the prevention or treatment of autoimmune pathologies or disorders linked to the appearance of antibodies directed against exogenous proteins
WO2007065691A2 (en) * 2005-12-07 2007-06-14 Technische Universität München Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Activation of platelet-rich plasma using thrombin receptor agonist peptide;Regina Landesberg et al.;《J Oral Maxillofac Surg》;20050401;第63卷(第4期);529-535 *

Also Published As

Publication number Publication date
KR20130112959A (ko) 2013-10-14
US8822638B2 (en) 2014-09-02
ES2739676T3 (es) 2020-02-03
PL2279200T3 (pl) 2017-08-31
ES2594706T3 (es) 2016-12-22
TW200944226A (en) 2009-11-01
US20160060295A1 (en) 2016-03-03
AU2009244635A1 (en) 2009-11-12
US9598464B2 (en) 2017-03-21
JP2017019797A (ja) 2017-01-26
EP3115370A1 (en) 2017-01-11
SG10201608071YA (en) 2016-11-29
CN102007140A (zh) 2011-04-06
US10822376B2 (en) 2020-11-03
HK1223946A1 (zh) 2017-08-11
US20190225648A1 (en) 2019-07-25
KR101434712B1 (ko) 2014-10-01
SG10201809286XA (en) 2018-11-29
TW201443085A (zh) 2014-11-16
BRPI0911203A2 (pt) 2016-07-05
DK3115370T3 (da) 2019-07-29
US20120077749A1 (en) 2012-03-29
NZ588200A (en) 2012-11-30
TWI573806B (zh) 2017-03-11
JP6038452B2 (ja) 2016-12-07
US20170174724A1 (en) 2017-06-22
WO2009137256A1 (en) 2009-11-12
US20150038676A1 (en) 2015-02-05
AR071478A1 (es) 2010-06-23
JP5977223B2 (ja) 2016-08-24
CA2721694C (en) 2018-11-06
US9206234B2 (en) 2015-12-08
KR101606248B1 (ko) 2016-03-24
US10287319B2 (en) 2019-05-14
HK1154255A1 (zh) 2012-04-13
KR20110005873A (ko) 2011-01-19
PT2279200T (pt) 2016-10-12
JP2014074052A (ja) 2014-04-24
US8563688B2 (en) 2013-10-22
MX2010011397A (es) 2010-11-12
AU2009244635B2 (en) 2012-04-19
EP3115370B1 (en) 2019-06-26
EP2279200A1 (en) 2011-02-02
TWI541020B (zh) 2016-07-11
US20100022445A1 (en) 2010-01-28
CN105524163A (zh) 2016-04-27
EP2279200B1 (en) 2016-07-13
CA2721694A1 (en) 2009-11-12
DK2279200T3 (en) 2016-08-22
JP2011518179A (ja) 2011-06-23

Similar Documents

Publication Publication Date Title
US10822376B2 (en) Biologically active peptides
AU2019202888B2 (en) Biologically active peptides
AU2012205202B2 (en) Biologically Active Peptides
HK1154255B (en) Biologically active peptides
HK1233275A1 (en) Biologically active peptides
HK1233275A (en) Biologically active peptides
HK1233275B (en) Biologically active peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154255

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160729

Address after: Illinois, USA

Patentee after: Baishen Co.

Patentee after: BAXALTA GmbH

Address before: Illinois, USA

Patentee before: Baxter International Inc.

Patentee before: BAXTER HEALTHCARE S.A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1154255

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210707

Address after: Osaka

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Illinois, USA

Patentee before: Baishen Co.

Patentee before: BAXALTA GmbH

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160224

CF01 Termination of patent right due to non-payment of annual fee